What is Abselion?
Founded in 2018 as HexagonFab within the University of Cambridge, Abselion has evolved into a specialized deep tech enterprise dedicated to simplifying complex protein research. The company's core value proposition lies in its ability to deliver compact, affordable, and highly efficient laboratory instrumentation. The Amperia platform represents the culmination of years of rigorous design and testing, offering a benchtop solution that addresses the critical need for streamlined workflows in modern biotechnology.
Abselion occupies a unique niche at the intersection of hardware engineering and molecular biology. By removing the friction associated with traditional protein analysis, the company empowers scientists to accelerate their research cycles. This market position is bolstered by a commitment to accessibility, ensuring that advanced diagnostic and research tools are not confined to elite institutions but are available to a broader spectrum of the scientific community.
How much funding has Abselion raised?
Abselion has raised a total of $8.4M across 1 funding round:
Series A
$8.4M
Series A (2024): $8.4M with participation from BGF, the Untitled Ventures, and Merck Ventures
Key Investors in Abselion
BGF
BGF is a prominent UK-based investment firm focused on providing growth capital to small and mid-sized businesses across diverse economic sectors.
the Untitled Ventures
The Untitled Ventures is an early growth stage fund specializing in deep tech startups, with a specific mandate to scale Eastern European innovation into global markets.
Merck Ventures
M Ventures serves as the strategic corporate venture capital arm of Merck, focusing on transformational technologies that align with the company's core scientific and commercial interests.
What's next for Abselion?
With the infusion of this major enterprise-level funding, Abselion is poised to enter an aggressive scaling phase. The strategic roadmap likely involves the global commercialization of the Amperia platform and the potential development of next-generation analytical tools. By leveraging the expertise of its diverse investor base, the company is set to solidify its footprint in the international biotech market.
The focus moving forward will be on operational excellence and market penetration. As Abselion continues to bridge the gap between academic innovation and industrial application, the company is expected to play a critical role in the future of proteomics. The support from institutional backers provides the stability required to navigate the complexities of the life sciences industry while maintaining a competitive edge in deep tech innovation.
